Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle.
about
Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndromeAntisense-mediated exon skipping: a versatile tool with therapeutic and research applicationsAMOD: a morpholino oligonucleotide selection toolNanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophySplicing therapy for neuromuscular diseaseAntisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistriesAnimal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapyPrevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice.Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo.Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel TherapiesModulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.Evaluation of Tris[2-(acryloyloxy)ethyl]isocyanurate cross-linked polyethylenimine as antisense morpholino oligomer delivery vehicle in cell culture and dystrophic mdx miceCationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouseIn vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.Impaired functional communication between the L-type calcium channel and mitochondria contributes to metabolic inhibition in the mdx heart.Dystrophin isoform induction in vivo by antisense-mediated alternative splicing.Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements.Microenvironmental regulation of telomerase isoforms in human embryonic stem cellsIn-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.The status of exon skipping as a therapeutic approach to duchenne muscular dystrophySilencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle GrowthChronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice.Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophyTherapeutic approaches to muscular dystrophy.Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.The impact of alternative splicing in vivo: mouse models show the way.Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy.In vivo correction of a Menkes disease model using antisense oligonucleotides.Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice.Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agentsNuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNASustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice.Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry.Therapeutic potential of splice-switching oligonucleotides.A gain of function mutation causing skeletal overgrowth in the rapunzel mutant.Recent molecular approaches to understanding astrocyte function in vivo.
P2860
Q24539118-E6FB0B57-028A-4685-9F7D-9084AB842DC1Q24682555-33A7097E-E516-4F08-8FE7-489E62839398Q24813042-1EFC5B10-C245-49D7-9565-C7FC73727960Q26992271-F014CD6E-D6E1-4540-A4F4-CE27CEB4C3A6Q27009581-C356EBCB-B037-4FFD-9FE3-88E003A5F23FQ27480935-83FE757D-C489-45FB-A945-083A78D3AF74Q28084979-BD13FF4D-5152-4700-AD15-0E45AE0D2E54Q30493685-7A9A000A-06FA-4013-A309-76E4059968A4Q33326762-59D59CBB-AC2C-4B6F-BBF2-5CC1CDBB90DFQ33525253-57732AC7-B9F6-4F1A-B04F-7CA439F48736Q33573648-2995C1F5-051F-4325-9E59-0931C2A6F0ACQ33608478-1C4F3407-AF05-4A9D-B6DE-07072F62B5ECQ33621929-29B0FA68-79C4-4F65-9FB8-7AD395B58F9DQ33637696-5911FADD-E1CF-40CD-80F5-E951DBEE3F30Q33713471-C73E64A0-1441-4964-969A-B3155834F85BQ33905151-59314A62-F4CD-49D0-A1C8-81DCE459298DQ33925699-B530349D-0C3D-4E88-A4B1-C608765E63B2Q33930110-115923E2-61A5-4024-89FA-8AC637F3CB49Q33980928-64D05F61-246E-4ED1-BAE8-A94225012BEBQ34081958-DBBB751F-5709-43EE-A715-EE77A2E35FB7Q34343780-AF220863-625B-4444-81EA-61AC7B3B5549Q34473309-F9CE8D74-6CBA-40E1-89E0-DFEFB66A014AQ34473336-A71264AF-C0B5-4E3D-989D-10266DC3E7A4Q34536058-CC152B76-3674-4C65-BC73-F0CCFDF806ABQ34556906-09DC21BA-6A4B-47AE-AA7E-CE150AB17ACEQ34695728-47743F0E-8C4B-4F87-AD03-92B27D57849DQ34982869-66BA85B6-6184-4984-A196-FB592696C7B5Q34994545-6E9F0AF8-C60F-4A4F-B57A-67393EC2F95FQ35084227-4DFC8AAF-1454-4061-B7F9-E39162C87B6AQ35902056-04F67F63-3EF1-4F32-AF29-2763A0A7AFE8Q36482835-215B3D43-C1EF-4B35-A55F-CB99913771FEQ36499173-86C0ECAF-3C91-4728-938D-A962C14F235DQ36690467-F627351C-6DA2-451E-8255-6AE7E3D3CBBBQ36925191-D8111027-4ACD-4837-96CD-BC70A12F7ED5Q37068616-D4615125-9A79-4E97-9888-DC560681169EQ37165327-F1A52A22-F89B-4246-B6B6-380A9E132C7EQ37276200-B02B4B7F-9CB3-4346-8B95-A381F270E1EDQ37363171-6443E75C-AD6C-4226-AF81-C564E85A5449Q37374581-EA3043D8-088F-47DA-88AF-47E23E5751C3Q37412106-973B23EB-7883-4F24-81CF-8E1721781654
P2860
Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Morpholino antisense oligonucl ...... skipping in mdx mouse muscle.
@en
Morpholino antisense oligonucl ...... skipping in mdx mouse muscle.
@nl
type
label
Morpholino antisense oligonucl ...... skipping in mdx mouse muscle.
@en
Morpholino antisense oligonucl ...... skipping in mdx mouse muscle.
@nl
prefLabel
Morpholino antisense oligonucl ...... skipping in mdx mouse muscle.
@en
Morpholino antisense oligonucl ...... skipping in mdx mouse muscle.
@nl
P2093
P356
P1476
Morpholino antisense oligonucl ...... 3 skipping in mdx mouse muscle
@en
P2093
Bianca L Gebski
Chrisopher J Mann
Stephen D Wilton
P304
P356
10.1093/HMG/DDG196
P50
P577
2003-08-01T00:00:00Z